← Back to patent-cliff list
Tadalafil Oral Soluble Film(Qilu Pharma)
Tier C — Watch / tradeTadalafil Oral Soluble Film(Qilu Pharma)
-
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PDE5A
Indications (approved)：Erectile dysfunction
Regional status
US
-
EU
-
China
Approved
2022-01-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tadalafil Oral Soluble Film(Qilu Pharma)?
Approved indications include: Erectile dysfunction.
When does the Tadalafil Oral Soluble Film(Qilu Pharma) patent expire?
No public expiry year is available for Tadalafil Oral Soluble Film(Qilu Pharma) yet; this page updates once verified.
How do I get a quote for Tadalafil Oral Soluble Film(Qilu Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27